This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Brain glioblastoma, helper endpoint
HLP_C3_GBM
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
588 |
4. Check minimum number of eventsNone |
588 |
5. Include endpointsNone |
588 |
6. Filter based on genotype QC (FinnGen only) |
518 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Brain glioblastoma, helper endpoint
based on the number of shared cases.
Similar with more cases:
- Brain glioblastoma
- Brain glioblastoma and astrocytoma
- Malignant neoplasm of brain
- Malignant neoplasm of eye, brain and central nervous system
- Malignant neoplasm of brain, including Hilmo
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 518 | 206 | 312 |
| Unadjusted period prevalence (%) | 0.12 | 0.07 | 0.14 |
| Median age at first event (years) | 65.75 | 66.29 | 65.39 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 550
- Matched controls
- 5500
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L01AX03
ATC
temozolomide; systemic
1096.6
307.7
378
11
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
922.4
307.7
401
16
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
62.5
307.7
208
53
N03AX14
ATC
levetiracetam; systemic
105.7
307.7
305
64
H02AB02
ATC
dexamethasone; systemic
98.7
307.7
486
393
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
36.7
307.7
266
137
130
Kela drug reimbursment
Malignant tumour
59.3
307.7
433
323
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
30.3
307.7
323
247
Z51.5
ICD-10 Finland
Palliative care
19.5
278.5
291
299
WF002
NOMESCO Finland
Radical radiotherapy
22.0
269.5
242
190
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
97.6
264.8
139
19
ZXC95
NOMESCO Finland
Use of surgical navigator
78.2
250.3
136
23
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
490.8
227.2
212
7
A04AA02
ATC
granisetron; systemic, transdermal
18.2
224.6
217
190
WF003
NOMESCO Finland
Adjuvant radiotherapy
26.5
221.5
167
89
C71.23
ICD-10 Finland
Malignant tumor of temporal lobe grade IV glioma
3269.0
219.0
197
*
C71.2
ICD-10 Finland
Malignant neoplasm: Temporal lobe
1221.7
184.6
170
*
9440/3-C71.9
ICD-O-3
Glioblastoma, NOS, of brain, NOS
+∞
181.6
164
*
A03FA01
ATC
metoclopramide; systemic, rectal
10.9
179.2
356
794
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
25.4
178.8
134
69
C71.13
ICD-10 Finland
Malignant tumor of frontal lobe grade IV glioma
+∞
174.5
158
*
9440/3-C71.2
ICD-O-3
Glioblastoma, NOS, of temporal lobe
+∞
158.2
144
*
C71.1
ICD-10 Finland
Malignant neoplasm: Frontal lobe
+∞
151.2
138
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
28.0
148.6
105
46
N03AX18
ATC
lacosamide; systemic
65.7
142.3
79
14
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
229.5
138.8
138
8
ZX095
NOMESCO Finland
Combined chemoradiotherapy
54.1
136.9
79
17
C71.20
ICD-10 Finland
Malignant tumor in temporal lobe without histology
777.6
129.0
122
*
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
23.7
126.5
95
48
C71.90
ICD-10 Finland
Malignant tumor in unspecified localization in the brain without histology
379.6
122.6
119
*
A04AA01
ATC
ondansetron; systemic, rectal
9.6
121.7
175
256
9440/3-C71.1
ICD-O-3
Glioblastoma, NOS, of frontal lobe
+∞
120.3
111
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
14.2
116.9
117
103
AA1AD
NOMESCO Finland
CT of head and brain
6.6
106.4
354
1181
C71.33
ICD-10 Finland
Malignant tumor of parietal lobe grade IV glioma
+∞
104.6
97
*
XX3DW
NOMESCO Finland
Time consuming IT work
7.3
102.4
195
384
AAG00
NOMESCO Finland
Stereotactic intracranial biopsy
583.3
101.0
97
*
C71.10
ICD-10 Finland
Malignant tumor in frontal lobe without histology
176.2
98.9
101
7
WX882
NOMESCO Finland
High dependency care
17.9
97.7
83
54
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
36.0
95.7
61
19
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
46.9
92.6
55
13
ZX050
NOMESCO Finland
Stereotactic radiotherapy
39.8
87.3
54
15
ZXC40
NOMESCO Finland
Use of ultrasound
47.7
81.2
48
11
C71.3
ICD-10 Finland
Malignant neoplasm: Parietal lobe
+∞
79.1
74
*
N05CD08
ATC
midazolam; nasal, systemic
13.8
77.8
76
63
YX8VG
NOMESCO Finland
Stereotactic MRI exmaination with high intensity magnet for dose design of radiotherapy
297.7
77.6
77
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.1
75.7
115
174
N03AF02
ATC
oxcarbazepine; oral
12.1
75.1
80
76
R56.8
ICD-10 Finland
Other and unspecified convulsions
8.8
70.1
97
131
C71.30
ICD-10 Finland
Malignant tumor in parietal lobe without histology
266.7
70.0
70
*
9440/3-C71.3
ICD-O-3
Glioblastoma, NOS, of parietal lobe
+∞
68.2
64
*
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
101.7
65.7
71
8
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.9
65.3
194
549
C71.83
ICD-10 Finland
Overall malignant tumor of the brain grade IV glioma
+∞
64.9
61
*
N74
ICPC
Malignant neoplasm nervous system
232.4
61.5
62
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.7
61.3
137
303
C71.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of brain
594.9
55.6
54
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
6.4
54.5
101
186
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
7.9
54.0
80
116
G40.9
ICD-10 Finland
Epilepsy, unspecified
9.4
52.1
66
79
ZXM40
NOMESCO Finland
Use of fluorescent substance
+∞
51.9
49
*
D43.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, unspecified
146.3
50.8
53
*
D43.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Central nervous system, unspecified
112.2
47.7
51
5
N02AA05
ATC
oxycodone; systemic
3.7
43.8
197
726
AA1BD
NOMESCO Finland
Extensive CT of head and brain
9.6
42.6
52
59
C71.99
ICD-10 Finland
Malignant tumor in unspecified localization in the brain other or unspecified histology
66.4
37.7
43
7
WF004
NOMESCO Finland
Palliative radiotherapy
9.9
37.0
44
48
A28
ICPC
Limited function/disability NOS
3.4
36.8
174
653
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
12.8
36.2
36
30
C71.93
ICD-10 Finland
Malignant tumor in an unspecified localization in the brain grade IV glioma
369.7
35.4
35
*
A79
ICPC
Malignancy NOS
10.4
34.2
39
40
AAA10
NOMESCO Finland
Biopsy through craniotomy
+∞
32.6
31
*
C71.43
ICD-10 Finland
Malignant tumor of the occipital lobe grade IV glioma
342.6
32.2
32
*
C71.29
ICD-10 Finland
Malignant tumor in temporal lobe other or unspecified histology
342.6
32.2
32
*
WX872
NOMESCO Finland
Intensive care
5.0
31.9
74
165
A98
ICPC
Health maint/preventive medicine
0.3
31.7
396
4919
R4120
NOMESCO Finland
Occupational therapy
4.6
31.2
81
198
C71.80
ICD-10 Finland
Overall malignant tumor of the brain without histology
169.5
31.0
32
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
8.8
29.4
38
46
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
9.3
29.2
36
41
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
28.6
166
690
A02BC02
ATC
pantoprazole; systemic
3.5
28.4
456
3208
WX402
NOMESCO Finland
General anaesthesia
2.8
27.4
184
826
WZC00
NOMESCO Finland
Treatment plan or consultation
2.6
27.3
264
1424
WZC30
NOMESCO Finland
Teaching
3.0
27.2
152
617
C71.9
ICD-10 Finland
Malignant neoplasm: Brain, unspecified
284.3
27.0
27
*
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
24.0
25.5
36
16
G40.10
ICD-10 Finland
Simple partial seizures
73.5
25.0
28
*
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
10.5
24.9
28
28
H53.4
ICD-10 Finland
Visual field defects
7.4
24.9
37
53
9440/3-C71.0
ICD-O-3
Glioblastoma, NOS, of cerebrum
+∞
24.1
23
*
N05CF01
ATC
zopiclone; oral
2.5
23.5
239
1297
R90.0
ICD-10 Finland
Intracranial space-occupying lesion
+∞
23.1
22
*
C71.40
ICD-10 Finland
Malignant tumor of the occipital lobe without histology
239.6
22.8
23
*
N76
ICPC
Neoplasm nervous system unspecified
125.2
22.8
24
*
C71.03
ICD-10 Finland
Malignant tumor of cerebellum except lobes and ventricles grade IV glioma
+∞
22.0
21
*
D43.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, infratentorial
228.7
21.8
22
*
K03.82
ICD-10 Finland
Split tooth for reasons other than trauma
0.2
21.3
23
1185
9440/3-C71.8
ICD-O-3
Glioblastoma, NOS, of overlapping lesion of brain
+∞
21.0
20
*
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
16.6
20.8
33
21
ZXE20
NOMESCO Finland
More than three and less than five hours
2.9
20.8
116
464
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
9.0
20.8
26
30
C71.4
ICD-10 Finland
Malignant neoplasm: Occipital lobe
217.9
20.7
21
*
N03AB02
ATC
phenytoin; systemic
8.6
20.7
27
33
WW200, ,
SPAT
0.2
20.6
30
1261
G41.9
ICD-10 Finland
Status epilepticus, unspecified
37.3
20.0
25
7
H02AB04
ATC
methylprednisolone; systemic
2.8
19.8
118
488
C71.00
ICD-10 Finland
Malignant tumor of the cerebrum except lobes and ventricles without histology
76.4
19.8
22
*
C71.19
ICD-10 Finland
Malignant tumor of frontal lobe other or unspecified histology
109.0
19.7
21
*
9440/3-C71.4
ICD-O-3
Glioblastoma, NOS, of occipital lobe
+∞
18.9
18
*
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
7.5
17.9
26
36
C71.22
ICD-10 Finland
Malignant tumor of temporal lobe grade III glioma
+∞
17.8
17
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
15.5
17.3
28
19
AA5BD
NOMESCO Finland
CT of cerebral ischaemia
6.0
17.3
31
54
XA800
NOMESCO Finland
Neuropsychological investigation
4.5
17.3
44
105
EB1VA, ,
NOMESCO Finland
0.1
16.5
9
627
N05BA09
ATC
clobazam; oral
31.1
16.2
21
7
GD1AA, ,
SPAT
0.1
16.2
6
553
N05BA04
ATC
oxazepam; oral
2.2
15.5
169
914
R4110
NOMESCO Finland
Physiotherapy
2.2
15.4
192
1095
I61.9
ICD-10 Finland
Intracerebral haemorrhage, unspecified
6.2
14.9
26
44
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
19.0
14.8
22
12
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
19.0
14.8
22
12
N03AG01
ATC
valproic acid; systemic, rectal
3.6
14.8
51
152
C10AA07
ATC
rosuvastatin; oral
0.4
14.4
66
1514
WX704
NOMESCO Finland
Intubation
3.1
14.2
64
225
WZC00, ,
SPAT
0.1
12.9
6
470
C71.0
ICD-10 Finland
Malignant neoplasm: Cerebrum, except lobes and ventricles
71.6
12.6
14
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
12.4
153
858
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
10.9
12.4
23
22
A10AB05
ATC
insulin aspart; parenteral
2.8
12.2
64
245
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.2
12.1
129
683
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
12.1
163
943
G40.11
ICD-10 Finland
Simple partial epileptic seizure that develops into a complex partial seizure
27.4
12.1
16
6
M79.6
ICD-10 Finland
Pain in limb
0.4
12.1
98
1803
R4130
NOMESCO Finland
Speech therapy
4.6
12.0
29
66
JN4AD
NOMESCO Finland
Body CT examination
2.4
12.0
95
444
C71
ICD-10 Finland
Malignant neoplasm of brain
+∞
11.5
11
*
C71.39
ICD-10 Finland
Malignant tumor of parietal lobe other or unspecified histology
122.5
11.5
12
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
4.0
11.3
32
83
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
9.5
11.1
22
24
C71.12
ICD-10 Finland
Malignant tumor of frontal lobe grade III glioma
44.3
11.0
13
*
Z76.0
ICD-10 Finland
Issue of repeat prescription
0.3
11.0
38
1020
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
12.3
10.9
19
16
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.4
10.6
81
372
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
0.5
10.5
102
1781
C71.21
ICD-10 Finland
Malignant tumor of temporal lobe grade II glioma
112.1
10.5
11
*
G93.6
ICD-10 Finland
Cerebral oedema
112.1
10.5
11
*
C71.32
ICD-10 Finland
Malignant tumor of parietal lobe grade III glioma
+∞
10.4
10
*
B01AB10
ATC
tinzaparin; parenteral
2.3
10.4
82
382
OAB42, ,
SPAT
0.2
10.4
8
446
R47.0
ICD-10 Finland
Dysphasia and aphasia
8.7
10.1
21
25
Z02.4
ICD-10 Finland
Examination for driving licence
0.4
10.1
67
1354
N05BA06
ATC
lorazepam; systemic, sublingual
3.1
9.9
43
148
Z71.8
ICD-10 Finland
Other specified counselling
0.4
9.8
62
1278
AWB00
NOMESCO Finland
Reoperation for superficial infection in surgery of the nervous system
56.0
9.7
11
*
M25.5
ICD-10 Finland
Pain in joint
0.4
9.6
61
1257
C10AX09
ATC
ezetimibe; oral
0.3
9.6
21
726
C71.50
ICD-10 Finland
Malignant tumor of cerebral ventricle without histology
+∞
9.4
9
*
WX892
NOMESCO Finland
Monitored bed care
2.6
9.1
56
232
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
3.3
8.9
33
103
SPAT1245
SPAT
Provision of support and information to patient’s family members
3.3
8.9
33
103
XF400
NOMESCO Finland
ECG with 12 standard connections
2.0
8.8
103
560
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
0.5
8.8
71
1344
EB4VA, ,
NOMESCO Finland
0.2
8.8
10
528
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
4.0
8.8
25
65
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
0.4
8.8
42
981
WZC30, ,
SPAT
0.1
8.8
*
298
H02AB09
ATC
hydrocortisone; systemic
4.7
8.7
20
44
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
11.8
8.6
15
13
L17
ICPC
Foot/toe symptom/complaint
0.4
8.5
59
1182
SAA02
NOMESCO Finland
Basic examination of mouth
0.6
8.4
202
2750
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
2.8
8.4
44
168
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
0.4
8.4
48
1041
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
4.3
8.3
21
50
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.6
8.2
50
206
L03
ICPC
Low back symptom/complaint
0.4
8.2
48
1034
ZXD10
NOMESCO Finland
Scheduled procedure
1.7
8.2
209
1449
XA400
NOMESCO Finland
EEG
17.5
8.1
12
7
R93.0
ICD-10 Finland
Abnormal findings on diagnostic imaging of skull and head, not elsewhere classified
33.9
8.1
10
*
WX110
NOMESCO Finland
Infiltration anesthesia
1.7
8.0
388
3179
N03AX23
ATC
brivaracetam; systemic
22.4
8.0
11
5
R41.0
ICD-10 Finland
Disorientation, unspecified
3.3
7.9
29
90
C07AB07
ATC
bisoprolol; oral
0.6
7.8
158
2268
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
3.6
7.8
25
71
G41.2
ICD-10 Finland
Complex partial status epilepticus
45.6
7.7
9
*
C71.01
ICD-10 Finland
Malignant tumor of cerebellum except lobes and ventricles grade II glioma
45.6
7.7
9
*
SFA10
NOMESCO Finland
One-surface restoration
0.6
7.7
160
2283
C10AA05
ATC
atorvastatin; oral
0.6
7.6
133
1989
WX725
NOMESCO Finland
Noninvasive ventilation
2.6
7.5
43
172
R03BB04
ATC
tiotropium bromide; inhalant
0.2
7.5
9
384
R23.8
ICD-10 Finland
Other and unspecified skin changes
0.4
7.4
33
801
OAB44, ,
SPAT
0.2
7.2
5
301
M75.1
ICD-10 Finland
Rotator cuff syndrome
0.4
7.2
52
1036
SDA03
NOMESCO Finland
Periodontal treatment
0.5
7.1
97
1564
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
10.2
7.1
13
13
D19
ICPC
Teeth/gum symptom/complaint
0.5
7.0
61
1139
N19
ICPC
Speech disorder
7.7
6.9
15
20
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
2.1
6.9
71
367
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.5
6.9
45
192
TKC20
NOMESCO Finland
Catheterisation of bladder
2.4
6.9
49
218
H25.1
ICD-10 Finland
Senile nuclear cataract
0.5
6.9
60
1119
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
0.4
6.8
30
734
D69.5
ICD-10 Finland
Secondary thrombocytopenia
16.9
6.8
10
6
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
22.8
6.7
9
*
SAA01
NOMESCO Finland
Simple examination of mouth
0.6
6.6
250
3137
Z01.2
ICD-10 Finland
Dental examination
0.6
6.6
115
1742
M54.4
ICD-10 Finland
Lumbago with sciatica
0.3
6.6
24
644
R01AD59
ATC
mometasone, combinations; nasal
0.0
6.6
*
163
OAB43, ,
SPAT
0.4
6.5
39
838
SFA30
NOMESCO Finland
Three-surface restoration
0.6
6.5
122
1811
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
7.5
6.4
14
19
I50.9
ICD-10 Finland
Heart failure, unspecified
0.3
6.4
16
521
ZSA00
NOMESCO Finland
Procedure related to previous procedure classified in chapter A
14.5
6.4
10
7
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.4
6.2
25
638
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
2.7
6.2
33
128
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
7.8
6.2
13
17
I25.1
ICD-10 Finland
Atherosclerotic heart disease
0.5
6.1
48
935
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
10.2
6.1
11
11
R03AC02
ATC
salbutamol; inhalant
0.6
6.0
172
2319
H02AB06
ATC
prednisolone; systemic
0.6
6.0
146
2044
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
234
0
+∞
267.15
1.0
0.0
—
—
—
0
0
147
29
68.81
263.50
1.7
1.7
—
—
—
0
0
100
0
+∞
107.95
1.1
0.0
—
—
—
0
0
289
860
5.97
97.04
1.8
1.9
26.43
29.47
s
14.99
280
838
243
662
5.78
89.05
5.3
9.5
1.12
1.07
mmol/l
0.09
194
558
243
669
5.72
87.80
5.3
9.4
4.91
5.17
kpa
5.28
238
647
243
669
5.72
87.80
5.3
9.4
17.73
12.14
kpa
26.00
238
650
52
36
15.85
58.64
1.0
1.3
—
—
—
0
0
53
48
12.11
50.92
1.6
1.1
—
—
—
0
0
274
1217
3.49
45.76
1.9
2.6
—
—
—
0
0
50
2144
0.16
42.93
1.4
2.0
1.44
1.37
mmol/l
0.29
41
1786
345
4693
0.29
40.69
3.4
5.5
4.81
4.56
mmol/l
3.95
314
4364
318
1637
3.23
40.02
2.8
2.1
146.72
214.61
u/l
1.99
313
1552
358
4767
0.29
39.91
3.7
6.3
2.93
2.66
mmol/l
5.04
326
4413
326
4547
0.31
38.84
4.6
6.9
39.43
39.86
mmol/mol
0.38
303
4252
345
4673
0.30
38.82
3.4
5.4
1.43
1.42
mmol/l
0.04
316
4318
33
23
15.20
36.79
1.5
1.1
—
—
—
0
0
260
1291
2.92
33.17
3.8
4.4
95.77
88.32
%
6.78
253
1266
60
109
6.06
32.34
1.7
1.2
43.11
13.36
e6/l
0.67
45
80
60
111
5.94
31.72
1.8
1.3
4049.54
1794.90
e6/l
0.33
46
86
348
4605
0.33
31.48
4.3
5.4
6.04
6.06
mmol/l
0.07
314
4227
64
128
5.53
31.14
1.5
1.2
817.48
504.44
mg/l
1.57
64
122
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
30
26
12.15
29.37
1.5
1.2
—
—
—
0
0
369
2312
2.81
28.55
6.1
7.1
1.19
1.21
mmol/l
7.06
364
2135
365
2292
2.76
27.80
2.5
2.9
—
—
estimate
—
0
0
338
4476
0.36
27.40
3.2
4.6
1.32
1.33
mmol/l
0.06
310
4116
414
2801
2.93
26.77
18.3
10.4
4.93
4.15
e9/l
8.25
349
2461
380
2561
2.57
22.96
7.0
7.9
1.20
1.21
mmol/l
2.56
347
2225
33
21
16.63
20.83
1.6
1.1
—
—
—
0
0
370
2560
2.36
19.56
10.5
6.5
1.33
1.91
e9/l
17.10
308
2263
101
388
2.96
19.43
5.9
10.5
0.96
1.33
%
6.78
101
383
374
2607
2.36
19.32
11.0
6.6
0.09
0.19
e9/l
43.35
304
2286
110
2136
0.39
17.37
2.3
3.0
202.83
152.85
ug/l
0.82
98
1982
341
4284
0.46
16.06
4.1
5.1
1.76
1.96
mu/l
2.73
314
3910
115
2142
0.41
15.96
1.8
2.4
72.65
76.95
nmol/l
0.93
108
1909
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
57
174
3.54
15.93
2.6
2.5
0.37
0.37
iu/ml
0.03
37
94
29
53
5.72
15.40
1.3
1.1
—
—
—
0
0
20
7
29.57
15.28
1.2
1.1
—
—
—
0
0
27
23
12.28
15.21
1.4
2.1
—
—
—
0
0
28
51
5.73
14.92
1.3
1.1
—
—
—
0
0
25
41
6.34
14.78
1.3
1.0
—
—
—
0
0
95
1838
0.42
13.85
2.8
3.4
8.75
7.81
mmol/l
0.78
80
1541
68
1503
0.38
13.46
1.4
1.7
17.35
20.34
nmol/l
1.72
62
1256
265
3552
0.51
13.37
3.5
4.1
14.86
14.91
pmol/l
0.10
245
3215
96
1825
0.43
13.22
3.6
4.1
12.40
7.72
mg/mmol
0.53
54
1146
59
207
3.07
13.15
2.0
2.2
161.62
316.17
ug/l
2.00
59
195
88
1710
0.42
12.65
2.0
3.2
495.86
1219.11
ng/l
8.55
76
1470
23
21
11.38
12.63
1.1
1.2
—
—
—
0
0
257
1721
1.93
12.57
10.5
3.7
2.36
2.35
mmol/l
0.16
248
1555
450
5024
0.43
12.16
40.9
26.3
7.52
6.73
e9/l
10.02
435
4921
450
5024
0.43
12.16
40.9
26.2
4.40
4.52
e12/l
6.24
435
4919
138
2245
0.49
12.07
1.8
2.1
92.56
95.59
pmol/l
0.39
73
1167
450
5021
0.43
11.98
41.1
26.3
227.21
243.66
e9/l
6.98
436
4931
334
2463
1.91
11.92
9.0
14.5
1.10
1.25
inr
7.78
299
2052
157
908
2.02
11.62
1.8
2.0
—
—
—
0
0
281
3590
0.56
10.27
2.8
4.5
11.79
12.19
mm/h
0.16
253
3347
18
17
10.90
9.84
1.4
1.1
—
—
—
0
0
28
807
0.31
9.10
1.1
1.3
14.22
9.57
u/ml
0.14
13
300
71
332
2.31
8.90
1.5
1.7
—
—
—
0
0
147
2203
0.55
8.89
3.6
5.3
2.01
2.28
ug/l
0.38
126
1994
115
653
1.96
8.71
1.6
1.9
—
—
—
0
0
13
8
16.59
8.59
1.1
1.0
—
—
—
0
0
121
703
1.92
8.56
1.7
1.9
—
—
—
0
0
127
1970
0.54
8.53
3.4
3.8
0.00
0.03
estimate
1.47
34
450
399
4553
0.55
8.39
28.1
17.0
87.59
79.08
ml/min/173m2
19.13
361
4257
111
1781
0.53
8.27
3.2
4.4
22.82
21.31
%
0.51
51
836
49
1036
0.42
7.99
1.3
1.2
1.28
1.76
u/ml
0.21
14
287
79
1385
0.50
7.66
2.1
2.9
338.37
355.48
umol/l
0.79
67
1203
89
484
2.00
7.57
2.1
7.4
6.89
9.87
mmol/l
5.44
83
463
60
1148
0.46
7.46
3.2
3.9
1.02
1.02
kg/l
0.23
48
781
39
881
0.40
7.41
1.1
1.3
10.76
36.17
iu/ml
—
8
266
292
2253
1.63
7.29
5.1
5.6
33.87
35.56
g/l
5.93
284
2105
131
828
1.76
6.95
2.1
3.2
2.39
1.57
e6/l
0.63
60
416
88
492
1.94
6.89
1.7
2.0
279.01
382.21
nmol/l
5.30
80
467
10
6
16.94
6.76
1.2
1.3
—
—
—
0
0
433
3750
1.73
6.37
16.6
9.0
66.83
80.51
u/l
21.81
427
3547
93
1481
0.55
6.37
3.2
3.9
0.00
0.01
estimate
0.78
35
500
9
5
18.26
6.28
1.2
1.2
—
—
—
0
0
204
2644
0.64
5.96
2.7
2.7
—
—
—
0
0
57
287
2.10
5.96
1.4
1.4
—
—
—
0
0
9
340
0.25
5.95
1.3
1.8
3.41
3.50
mmol/l
—
9
259
198
1444
1.58
5.91
2.4
3.3
0.47
0.51
e6/l
0.10
140
1062
12
15
8.15
5.86
1.3
1.1
—
—
—
0
0
81
1316
0.55
5.86
2.5
3.1
0.56
0.73
ug/l
2.97
54
836
150
1026
1.64
5.83
3.0
4.1
54.89
440.16
ng/l
4.23
122
841
79
1278
0.55
5.59
1.6
2.2
3.13
2.98
mg/l
0.16
64
1107
11
13
8.61
5.58
1.1
1.2
—
—
—
0
0
134
900
1.65
5.57
2.2
3.1
1.59
0.97
e6/l
0.51
65
485
15
28
5.48
5.57
1.0
1.0
1.14
1.14
u/l
—
9
17
204
2620
0.65
5.55
3.0
3.9
0.00
2.96
estimate
0.50
43
549
110
1624
0.60
5.50
2.4
2.8
51.20
66.04
u/l
2.57
103
1506
203
2592
0.66
5.25
3.0
3.9
0.00
0.00
estimate
-0.00
39
535
5
0
+∞
5.21
1.2
0.0
—
—
—
0
0
38
174
2.27
5.03
1.9
1.9
—
—
—
0
0
28
112
2.58
4.95
2.1
6.8
128.17
143.78
iu/ml
—
6
18
14
423
0.31
4.88
1.1
1.4
—
—
—
0
0
211
2648
0.67
4.84
3.0
3.9
0.00
0.61
estimate
0.52
39
506
140
1009
1.52
4.19
3.9
3.2
2.46
2.45
mmol/l
0.05
129
910
19
68
2.86
4.16
1.2
2.0
—
—
—
0
0
67
1053
0.59
4.11
1.4
1.8
461.24
24569896.64
pmol/l
0.94
54
871
24
98
2.52
4.10
1.3
1.4
—
—
—
0
0
24
98
2.52
4.10
1.3
1.4
—
—
—
0
0
7
7
10.11
4.02
1.3
1.3
—
—
—
0
0
9
14
6.51
3.99
1.3
1.1
—
—
—
0
0
9
14
6.51
3.99
1.3
1.1
—
—
—
0
0
100
1411
0.64
3.85
3.1
3.3
0.00
0.06
estimate
0.58
30
432
9
15
6.08
3.83
1.3
1.1
—
—
—
0
0
9
15
6.08
3.83
1.3
1.1
—
—
—
0
0
13
33
4.01
3.81
1.1
1.0
—
—
—
0
0
211
1677
1.42
3.75
2.6
3.4
31.50
97.11
e6/l
0.96
150
1296
32
159
2.08
3.52
1.4
2.4
3.46
3.63
g/l
0.29
32
154
6
7
8.65
3.27
1.5
1.3
—
—
—
0
0
16
61
2.67
3.16
1.8
2.6
—
—
—
0
0
8
17
4.76
2.93
1.0
1.1
—
—
—
0
0
36
600
0.57
2.73
1.4
1.9
1.42
1.53
%
0.44
28
514
8
216
0.36
2.72
1.6
1.9
36.75
39.48
nmol/l
—
8
208
8
19
4.26
2.68
1.5
1.4
—
—
—
0
0
27
484
0.54
2.64
1.6
2.1
3.52
3.58
ratio
0.08
27
403
43
674
0.61
2.57
1.2
1.4
—
—
—
0
0
11
37
3.01
2.50
1.4
1.2
—
—
—
0
0
23
117
2.01
2.44
1.2
1.5
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
12
5.04
2.40
1.0
1.9
191.00
135.17
%
—
6
12
5
8
6.29
2.37
1.2
1.0
—
—
—
0
0
32
187
1.76
2.26
2.2
2.1
—
—
—
0
0
13
54
2.44
2.21
1.2
1.1
—
—
—
0
0
73
526
1.45
2.16
2.1
3.4
2.15
1.90
mmol/l
0.31
68
460
9
30
3.03
2.15
2.4
3.2
1.56
1.07
%
—
9
30
27
453
0.58
2.12
3.5
2.5
0.86
0.50
e6/l
0.22
27
435
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
5
10
5.03
2.07
1.0
1.1
97.60
103.10
%
—
5
10
14
63
2.25
2.02
1.2
2.1
—
—
—
0
0
16
306
0.51
1.96
1.5
1.9
—
—
—
0
0
26
152
1.75
1.86
1.3
1.7
—
—
—
0
0
0
47
0.00
1.71
0.0
1.3
—
—
—
0
0
15
277
0.53
1.67
1.5
1.8
—
—
—
0
0
36
530
0.66
1.66
1.6
2.6
0.27
0.21
g/l
4.25
36
498
46
638
0.70
1.57
3.4
5.1
30.06
31.73
%
0.62
34
404
6
136
0.44
1.42
1.2
1.2
—
1.34
—
0
7
5
121
0.41
1.39
1.0
1.1
—
10.04
—
0
11
0
39
0.00
1.34
0.0
1.5
—
24.00
—
0
5
43
585
0.71
1.33
8.0
7.5
—
—
—
0
0
0
40
0.00
1.33
0.0
1.6
—
29.80
—
0
5
6
131
0.45
1.30
1.2
1.2
—
2.63
—
0
18
6
131
0.45
1.30
1.2
1.3
—
3.23
—
0
22
8
159
0.50
1.26
1.1
1.3
—
—
—
0
0
5
116
0.43
1.26
1.2
3.9
40.80
435.27
u/ml
—
5
110
446
4637
0.80
1.24
28.4
17.4
17.89
24.92
mg/l
10.68
431
3853
44
586
0.73
1.21
2.2
4.6
3.22
29.67
ug/l
1.24
27
499
6
126
0.47
1.18
1.2
1.2
—
—
—
0
0
10
50
2.02
1.17
1.3
1.5
0.84
1.22
promille
—
10
44
67
835
0.77
1.16
1.5
1.7
849.75
1206.48
nmol/l
4.54
51
633
0
34
0.00
1.16
0.0
8.0
—
36.40
—
0
10
95
1135
0.80
1.16
1.6
1.7
3.19
1.34
mg/l
1.53
84
893
23
151
1.55
1.13
1.7
2.2
211.30
198.48
%
0.28
23
145
17
266
0.63
1.09
1.2
1.2
102.75
128.54
u/ml
—
6
104
8
41
1.97
1.09
1.3
1.2
—
—
—
0
0
36
485
0.72
1.08
1.3
1.5
—
—
—
0
0
18
114
1.60
1.04
1.1
1.1
—
3.73
—
0
15
12
201
0.59
1.02
1.3
4.3
34.12
81.71
mg/l
—
6
174
12
200
0.59
1.00
1.3
4.3
20.19
41.26
mg/l
—
7
174
12
199
0.59
0.99
1.0
1.0
—
—
—
0
0
0
30
0.00
0.97
0.0
1.1
—
—
—
0
0
0
31
0.00
0.96
0.0
1.8
—
109.21
—
0
31
66
537
1.26
0.96
3.8
3.4
—
—
—
0
0
45
349
1.32
0.94
2.3
3.1
138.11
128.56
g/l
3.53
45
340
39
298
1.33
0.90
1.3
1.4
—
56.17
—
0
23
33
246
1.36
0.89
2.8
3.5
25.54
25.27
mmol/l
0.21
33
236
17
111
1.55
0.88
1.2
1.3
—
—
—
0
0
75
626
1.23
0.88
1.9
3.0
4.86
8.45
umol/l
4.14
67
566
224
2056
1.15
0.87
3.7
3.9
17.40
67.72
ng/l
1.27
196
1567
12
187
0.63
0.79
1.3
4.1
1.85
2.85
ratio
—
5
111
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
7
123
0.56
0.78
1.1
1.3
—
—
—
0
0
5
97
0.51
0.78
1.4
1.5
—
—
—
0
0
9
143
0.62
0.70
1.1
1.6
—
—
—
0
0
26
196
1.34
0.69
4.5
4.1
1.54
1.37
mmol/l
0.58
26
189
27
206
1.33
0.66
1.8
3.1
—
—
—
0
0
5
28
1.79
0.66
1.0
3.0
126.00
92.75
%
—
5
28
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
10
151
0.66
0.60
2.4
2.5
183.60
90.04
ug/min
—
5
84
0
21
0.00
0.60
0.0
1.1
—
250.60
—
0
21
0
21
0.00
0.60
0.0
1.9
—
42.33
—
0
21
30
374
0.79
0.58
1.1
1.6
—
—
—
0
0
6
35
1.72
0.58
3.8
3.5
0.67
0.94
index
—
6
35
33
404
0.81
0.55
5.9
2.6
73.29
64.81
ml/min/173m2
0.72
14
174
7
106
0.66
0.49
1.1
3.0
5.30
9.34
pmol/l
—
7
106
37
310
1.21
0.47
1.7
3.2
1.77
2.04
mmol/l
0.24
32
232
8
56
1.43
0.42
1.4
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
11
149
0.73
0.40
1.2
2.3
11.75
12.38
mg/l
0.15
11
140
0
19
0.00
0.39
0.0
1.3
—
9.31
—
0
19
10
136
0.73
0.38
1.9
1.5
—
—
—
0
0
8
114
0.70
0.37
1.5
1.5
—
—
—
0
0
315
3246
0.93
0.34
4.0
3.5
69.52
54.75
u/l
0.68
305
3048
20
165
1.22
0.31
1.6
2.0
119.50
90.08
%
4.05
20
160
51
459
1.12
0.30
1.4
2.4
2.48
7.49
ug/l
7.65
43
420
16
132
1.22
0.26
1.3
1.5
—
—
—
0
0
21
244
0.86
0.24
2.1
3.7
15.07
5338.56
u/ml
0.73
15
212
10
126
0.79
0.24
1.4
1.2
—
—
—
0
0
5
38
1.32
0.23
1.8
1.6
—
—
—
0
0
16
134
1.20
0.23
4.2
3.2
2.18
1.93
index
0.09
11
83
17
200
0.85
0.23
1.4
1.3
—
—
—
0
0
5
42
1.19
0.21
1.0
2.9
1340.40
687.45
mg
—
5
42
0
11
0.00
0.21
0.0
10.5
—
10.16
—
0
11
0
11
0.00
0.21
0.0
1.0
—
27.16
—
0
11
0
11
0.00
0.21
0.0
2.6
—
35.00
—
0
11
0
10
0.00
0.21
0.0
2.3
—
2.58
—
0
5
32
287
1.12
0.21
3.3
3.7
51.30
48.28
%
0.28
32
281
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
8
105
0.76
0.21
1.5
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
8.61
—
0
7
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
12
144
0.83
0.20
1.0
1.2
—
—
—
0
0
7
60
1.17
0.18
1.1
1.7
—
—
—
0
0
7
62
1.13
0.17
1.4
1.5
1.04
30.44
nmol/l
—
7
57
5
66
0.76
0.17
1.6
1.3
214.20
277.17
pmol/l
—
5
58
5
69
0.72
0.17
1.0
1.2
7.00
7.49
mmol/l
—
5
58
6
80
0.75
0.15
1.0
1.1
1.43
1.53
g/l
—
6
75
17
151
1.13
0.13
1.2
1.6
—
—
—
0
0
11
127
0.86
0.12
1.4
1.1
—
—
—
0
0
5
44
1.14
0.10
1.4
1.7
—
—
—
0
0
5
48
1.04
0.09
1.2
1.1
—
—
—
0
0
7
66
1.06
0.08
1.6
1.6
—
—
—
0
0
8
77
1.04
0.07
1.3
1.6
—
—
—
0
0
169
1717
0.98
0.07
5.7
3.5
28.05
33.83
u/l
2.57
164
1617
10
112
0.89
0.07
1.4
1.6
—
—
—
0
0
47
488
0.96
0.07
1.8
2.6
31.73
34.32
u/l
0.31
41
410
10
93
1.08
0.02
1.4
1.6
—
—
—
0
0
20
193
1.04
0.01
2.0
3.6
25.04
25.02
mmol/l
0.02
20
178
12
125
0.96
0.00
1.2
1.5
—
—
—
0
0
14
145
0.96
0.00
4.3
3.1
1.61
1.58
mmol/l
0.08
14
140
16
163
0.98
0.00
1.1
1.3
—
—
—
0
0
116
1165
0.99
0.00
2.5
2.6
6.21
4.16
e6/l
0.86
107
1072
16
161
0.99
0.00
1.2
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.19
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.5
—
83.55
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
11
110
1.00
-0.00
1.4
1.4
24.05
26.28
iu/l
0.09
11
89
7
70
1.00
-0.00
1.3
1.6
—
—
—
0
0
7
73
0.96
-0.00
1.0
1.1
—
—
—
0
0
40
400
1.00
-0.00
2.6
4.2
1.23
1.22
mmol/l
0.32
40
350
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: HLP_C3_GBM – Brain glioblastoma, helper endpoint
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).